Difference between revisions of "Gene function"
Farmakorakel (talk | contribs) (Created page with "Next generation sequencing (NGS) leads to the discovery of many new genetic variants. A challenge is how to evaluate the functional consequences of these mutations. A disc...") |
Farmakorakel (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | Next generation sequencing ([[NGS]]) leads to the discovery of many new genetic variants. A challenge is how to evaluate the functional consequences of these mutations. A discussion of this is given by [https://www.researchgate.net/profile/Magnus_Ingelman-Sundberg Ingelman-Sundberg] ''et al.'' in the article [https://doi.org/10.1186/s40246-018-0157-3 Integrating rare genetic variants into pharmacogenetic drug response predictions]. A potenitally very interesting reference in that work (currently in reviview), is called ''An optimized prediction framework to assess the functional impact of pharmacogenetic variants'', by [https://www.researchgate.net/scientific-contributions/2125612086_Yitian_Zhou Yitian Zhou] in [https://www.researchgate.net/profile/Volker_Lauschke2 Volker Lauschke]'s group at the Department of Physiology and Pharmacology at Karolinska Institutet. | + | Next generation sequencing ([[NGS]]) leads to the discovery of many new genetic variants, as outlined in [https://doi.org/10.2217/pgs-2016-0023 Requirements for comprehensive pharmacogenetic genotyping platforms]. A challenge is how to evaluate the functional consequences of these mutations. A discussion of this is given by [https://www.researchgate.net/profile/Magnus_Ingelman-Sundberg Ingelman-Sundberg] ''et al.'' in the article [https://doi.org/10.1186/s40246-018-0157-3 Integrating rare genetic variants into pharmacogenetic drug response predictions]. A potenitally very interesting reference in that work (currently in reviview), is called ''An optimized prediction framework to assess the functional impact of pharmacogenetic variants'', by [https://www.researchgate.net/scientific-contributions/2125612086_Yitian_Zhou Yitian Zhou] in [https://www.researchgate.net/profile/Volker_Lauschke2 Volker Lauschke]'s group at the Department of Physiology and Pharmacology at Karolinska Institutet. |
The same authors also propose a high-throughput ''in vitro'' method for gene function evaluation in [https://doi.org/10.2217/pgs-2018-0096 Human liver spheroids in chemically defined conditions for studies of gene–drug, drug–drug and disease–drug interactions]. This idea is the basis of the company [http://www.hepapredict.com/technology HepaPredict AB]. | The same authors also propose a high-throughput ''in vitro'' method for gene function evaluation in [https://doi.org/10.2217/pgs-2018-0096 Human liver spheroids in chemically defined conditions for studies of gene–drug, drug–drug and disease–drug interactions]. This idea is the basis of the company [http://www.hepapredict.com/technology HepaPredict AB]. | ||
Revision as of 08:31, 29 August 2018
Next generation sequencing (NGS) leads to the discovery of many new genetic variants, as outlined in Requirements for comprehensive pharmacogenetic genotyping platforms. A challenge is how to evaluate the functional consequences of these mutations. A discussion of this is given by Ingelman-Sundberg et al. in the article Integrating rare genetic variants into pharmacogenetic drug response predictions. A potenitally very interesting reference in that work (currently in reviview), is called An optimized prediction framework to assess the functional impact of pharmacogenetic variants, by Yitian Zhou in Volker Lauschke's group at the Department of Physiology and Pharmacology at Karolinska Institutet.
The same authors also propose a high-throughput in vitro method for gene function evaluation in Human liver spheroids in chemically defined conditions for studies of gene–drug, drug–drug and disease–drug interactions. This idea is the basis of the company HepaPredict AB.
